Key result
SGLT2i use in a real-world heart failure cohort was not significantly associated with HF hospitalization after propensity score adjustment (HR 0.91; 95% CI 0.57-1.47; P=0.700).
Why the study?
The prevalence of SGLT2 inhibitor use, baseline laboratory profiles, and associated clinical outcomes in a real-world heart failure cohort were not well characterized.
Does SGLT2 inhibitor use reduce heart failure hospitalization in a real-world heart failure cohort?
Cohort (n=581)
No
Does SGLT2 inhibitor use reduce heart failure hospitalization in a real-world heart failure cohort?
Hazard Ratio: 0.91 (95% CI 0.57–1.47)
p-value: p=0.700
In real-world settings, SGLT2i use in heart failure is subject to significant treatment selection bias where patients with more advanced disease receive the therapy, obscuring its therapeutic benefit in unadjusted analyses.
No basis to alter SGLT2i use in HF from this cohort; leaves open real-world effectiveness pending RCTs.
OBJECTIVE: To evaluate the prevalence of sodium-glucose co-transporter 2 inhibitor (SGLT2i) use, baseline laboratory profiles, and associated clinical outcomes in a real-world heart failure (HF) cohort. METHOD: This retrospective, single-center cohort study included consecutive patients with HF who were evaluated between January 2022 and January 2024. Of the 609 patients, 581 with known SGLT2i use status constituted the analytic cohort. The primary outcome was HF hospitalization. A composite outcome comprising all-cause death, HF hospitalization, stroke, or peripheral embolism was assessed as an exploratory endpoint. Propensity score matching and overlap-weighted Cox regression models were used in sensitivity analyses. RESULTS: Among the 581 patients, 349 were SGLT2i users and 232 were non-users. Users had a lower left ventricular ejection fraction, higher B-type natriuretic peptide concentrations, a higher prevalence of diabetes and ischemic etiology, and more intensive background therapy. In the unadjusted analyses, the rates of HF hospitalization and composite events were higher among users; however, these associations were attenuated after adjustment. In the overlap-weighted propensity score analysis, SGLT2i use was not associated with HF hospitalization (HR: 0.91; 95% CI: 0.57-1.47; P=0.700), the study-defined composite endpoint (HR: 0.95; 95% CI: 0.61-1.48; P=0.827), or exploratory all-cause mortality (HR: 1.04; 95% CI: 0.45-2.42; P=0.931). CONCLUSION: SGLT2i users represented a treated population with more advanced clinical characteristics, and their higher unadjusted event burden did not persist after adjustment. These findings reflect treatment selection rather than therapeutic benefit or harm. Therapies proven to reduce mortality should be systematically implemented in all eligible patients with HF, regardless of their clinical status or estimated mortality risk.
No takes yet. Share an insight, caveat, or question.
Yavuz et al. (2026) conducted a cohort in Heart failure (HF) (n=581). Sodium-glucose co-transporter 2 inhibitor (SGLT2i) vs. Non-users was evaluated on HF hospitalization (HR 0.91, 95% CI 0.57-1.47, p=0.700). SGLT2i use in a real-world heart failure cohort was not significantly associated with HF hospitalization after propensity score adjustment (HR 0.91; 95% CI 0.57-1.47; P=0.700).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: